Trial Profile
First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Lexaptepid pegol (Primary) ; Lexaptepid pegol (Primary)
- Indications Anaemia
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors NOXXON Pharma AG
- 28 Apr 2014 New trial record